Table 3.
Tumour characteristics and treatment in NASH vs non-NASH-HCC
| Characteristics | NASH - HCC | Non-NASH - HCC | P |
|---|---|---|---|
| (n = 45) | (n = 1074) | ||
| (n [%]) | (n [%]) | ||
| Histological confirmation of HCC | 39 (86.7) | 939 (87.4) | 1.000 |
| Grading | |||
| G1 | 9 (20) | 233 (21.7) | 1.000 |
| G2 | 20 (44.4) | 438 (40.8) | 0.781 |
| G3 | 6 (13.3) | 162 (15.1) | 1.000 |
| Median tumour size (cm)# | 6 (1.5-16.5) | 4.8 (0–28) | 0.176 |
| Metastases at initial diagnosis | |||
| Lymph nodes | 2 (4.4) | 62 (5.8) | 1.000 |
| Distant | 5 (11.1) | 87 (8.1) | 0.423 |
| Morphology | |||
| solitaire | 9 (20) | 319 (29.7) | 0.324 |
| multifocal | 36 (80) | 749 (69.7) | 0.565 |
| no data | 0 | 6 (0.6) | 1.000 |
| BCLC at HCC diagnosis | |||
| BCLC A | 9 (20) | 258 (24) | 0.727 |
| BCLC B | 11 (24.4) | 179 (16.7) | 0.248 |
| BCLC C | 19 (42.2) | 458 (42.6) | 1.000 |
| BCLC D | 6 (13.3) | 173 (16.1) | 0.836 |
| no data | 0 | 6 (0.6) | 1.000 |
| UICC | |||
| I | 7 (15.6) | 278 (25.9) | 0.290 |
| II | 11 (24.4) | 320 (29.8) | 0.629 |
| III | 22 (48.9) | 374 (34.8) | 0.203 |
| VI | 0 | 0 | 1.000 |
| Primary therapy | |||
| Resection | 8 (17.8) | 213 (19.8) | 1.000 |
| OLT | 0 | 43 (4) | 0.407 |
| OLT after bridging | 2 (4.4) | 188 (17.5) | 0.054 |
| TACE | 19 (42.2) | 503 (46.8) | 0.785 |
| RFA/PEI | 2 (4.4) | 55 (5.1) | 1.000 |
| Chemotherapy | 1 (2.2) | 22 (2) | 0.615 |
| Sorafenib | 8 (17.8) | 38 (3.5) | <0.001 |
| Best supportive care | 3 (6.7) | 120 (11.2) | 0.619 |
| Overall survival (months)# | 11.28 (0.7-127.6) | 15.5 (0–131.3) | 0.287 |
#Data presented in (median [range]). A p value p<0.05 was considered significant and is marked in bold.